HBV感染,家族肝癌史与ABO血型在低发区原发性肝癌的关系

本文研究了高，低发区５１０例ＰＨＣＨＢＶ感染、家庭肝癌史及与ＡＢＯ血型的关系，结果表明：１肝癌低发区与高发区一样，全并ＨＢＶ感染的ＰＨＣ患者达８０．７４％，远多于元ＨＶＣ感染者；２低发区ＰＨＣ中，有家族肝癌史的Ａ型血者显著多于相应对照组。     

ABO血型与PHC患者HBV感染标记相关性研究

研究伴ＨＢＶ感染的ＰＨＣ４４５例乙型肝炎抗原抗体与ＡＢＯ血型的关系，结果表明：１．伴ＨＢＶ感染的ＰＨＣＡ型血者显著高于对照组（Ｐ＜０．０１）。２．ＰＨＣ患者中ＨＢｓＡｇ、抗－ＨＢｃ的阳性率均以Ａ型血显著高于对照组（Ｐ＜０．０５）。３．ＰＨＣ患者中ＨＢｓＡｇ与抗－ＨＢｃ均阳性模式Ａ型血者显著多于对照组，而Ｂ型血者显著少（Ｐ＜０．０５）；抗－ＨＢｅ与抗ＨＢｃ均阳性的ＰＨＣ中，亦为Ａ型血者显著多（Ｐ＜０．０５）。提示有ＨＢＶ感染的Ａ型血者罹患ＰＨＣ的倾向性最高；而有ＨＢＶＭ、ＨＢｓＡｇ、抗－ＨＢｃ的Ａ型血者则为ＰＨＣ的易感人群，其中以ＨＢｓＡｇ和抗－ＨＢｃ同时阳性或抗－ＨＢｅ和抗－ＨＢｃ同时阳性的感染模式更易发生ＰＨＣ；也提示ＰＨＣ、ＨＢＶ、Ａ型血三者之间存在某种密切的、复杂的联系，对ＰＨＣ的发生有协同作用。对上述人群应密切关注，定期复查，以期早诊早治。     

家族肿瘤史在肝炎与原发性肝癌关系中的作用

研究ＰＨＣ９２４例中家族肿瘤史对肝炎与ＰＨＣ关系的影响，结果表明：①合并ＨＢＶ感染的ＰＨＣ、乙肝组中有家族肿瘤史的患者均显著多于非乙肝组和无肝炎组（Ｐ＜０．０１～０．０５）。②乙肝组发病高峰年龄为３０～４９岁，显著高于其它两组（５０～５９，Ｐ＜０．０１）；乙肝组中有家族肿瘤史者发病高峰年龄为３０～３９岁，显著高于无家族肿瘤史者（４０～４９岁，Ｐ＜０．０１）。③肝炎后至发生临床肝癌时间乙肝组以５～９年居多，较非乙肝组１０～１４年居多提前一个年龄组（Ｐ＜０．０５），且有家族肿瘤史者比例显著高（Ｐ＜０．０５）。提示ＨＢＶ感染可促使ＰＨＣ的高发、早发，而家族肿瘤史则加速了这一进程。     

陕北原发性肝癌与HBV感染关系的研究

 目的　研究陕北地区原发性肝癌与HBV感染的关系。方法　收集陕北地区三所地区级医院病例组与对照组各 88例 ,进行对照分析研究。结果　HBV感染与个人肝病史有协同作用 ,本文中有肝病史者患肝癌的危险性是无肝病史者的 1 9.1 74倍。结论　我们认为HBV感染是陕北原发性肝癌的主要危险因素     

原发性肝癌的发病与HBV感染及性别的关系

原发性肝癌的发病中乙型肝炎病毒(HBV)感染是主要因素之一。乙型肝炎表面抗原 (HBs Ag)阳性者其肝癌的相对危险性为 HBs Ag阴性的 10倍～ 5 0倍。我国肝癌患者 HBV感染标记物阳性者达 90 %左右。原发性肝癌患者的另一个显著特点是男性多于女性 ,男女比例约为 2～ 5∶ 1[1 ]。本     

肝癌患者一级亲属HBV感染的调查分析

本文从ＨＢＶ感染的角度研究肝癌家族内的遗传效应。提示ＰＨＣ患者一级亲属确是一组ＨＢＶ易感人群，且肝癌家族内ＨＢＶ感染、ＰＨＣ都呈明显的、以母系亲代传递为特征的家族聚集现象；ＨＢＶ经垂直感染可导致家族性ＰＨＣ，ＰＨＣ患者同胞是ＨＢＶ、ＰＨＣ最易感人群。因此，对该人群需密切关注，定期复查，警惕ＰＨＣ的发生。     

原发性肝癌与HBV DNA的关系分析

目的：探讨原发性肝癌（PHCC）与患者血清乙肝病毒（HBV）的关系。方法：对286例PHCC患者进行HBV DNA检测。结果：在286例肝癌患者中，HBV DNA阳性率为62．59％，其中85．47％的感染者血清HBV DNA水平≤10^6。结论：乙肝病毒感染仍是肝癌的主要发病因素，而且这类患者的血清HBV DNA水平大多较低。     

HBV感染与肝癌关系的新进展

原发性肝癌（primary liver cancer，PLC）。简称肝癌）在世界上广泛流行，在我国肿瘤死因中占第2位，在部分农村占首位，据国际癌症研究中心估计，2000年全球肝癌发病56．4万例，其中中国30．6万例。肝癌起病隐匿、发展迅速、预后凶险，有“癌王”之称，严重威胁人民的生命和健康。在肝癌病因学方面，目前倾向于多因素、多步骤发生且各因素间有交互作用的观点。其中在病毒病因中，国内外研究结果一致认为，HBV持续感染是肝癌最重要的病因之一，在发展中国家尤为突出。WHO肝癌预防会议指出：HBV与肝癌相关性高达80％。本文主要简述近年HBV与肝癌研究的新进展。     

肝癌患者一级亲属HBV感染的调查分析

本文从ＨＢＶ感染的角度研究肝癌家族内的遗传效应。结果表明：１，原发性肝癌（ＰＨＣ）患者一级亲属２２７人。其乙型肝炎病毒感染标记（ＨＢＶＭ）阳性率为７１．８１％，ＨＢｓＡｇ阳性率为４２．７３％，显著高于当地的自然人群（Ｐ＜０．０５）；其ＨＢＶＭ最常见模式是ＨＢｓＡｇ、抗－ＨＢｅ和抗－ＨＢｃ同时阳性，与有ＨＢＶ感染的ＰＨＣ患者ＨＢＶＭ的最常见模式相一致。２．患者同胞的ＨＢＶＭ阳性率为８２，９８％，ＨＢｓＡｇ为５１．０％，均显著高于患者双亲、子代（Ｐ＜０．０５）；且男性显著多于女性（Ｐ＜０．０５）。３．患者母亲组的ＨＢＶＭ明显高于父亲组（＋３１．４３％）。提示ＰＨＣ患者一级亲属确是一组ＨＢＶ易感人群，且肝癌家族内ＨＢＶ感染、ＰＨＣ都呈明显的、以母系亲代传递为特征的家族聚集现象；ＨＢＶ经垂直感染可导致家族性ＰＨＣ，ＰＨＣ患者同胞（尤其男性）是ＨＢＶ、ＰＨＣ最易感人群。因此，对该人群需密切关注，定期复查，警惕ＰＨＣ的发生。     

ABO Blood Group,Epstein-Barr virus Infection and Prognosis of Patients with Non-metastatic Nasopharyngeal Carcinoma

Background: A prior study showed blood type A/AB to be associated with an increased risk of nasopharyngeal carcinoma (NPC) compared to subjects with blood type O. However, the relationship between ABO blood groups and prognosis of NPC patients is still questionable. In addition, whether Epstein-Barr virus (EBV) infection is associated with prognosis of NPC patients with different ABO blood groups is unclear. Materials and Methods: We conducted univariate and multivariable Cox regression analyses based on a consecutive cohort of 1,601 patients to investigate the above issues. Results: There was no significant difference in overall survival (OS) between different ABO blood groups (p=0.629), neither between A vs. non-A blood groups (p=0.895) nor AB vs. non-ABblood group (p=0.309) in univariate analyses and after adjusting for other factors. Interaction tests revealed that high immunoglobulin A against Epstein-Barr virus viral capsid antigen (VcA-IgA) level was associated with a favorable prognosis in male patients with UICC stage II disease who had an A blood type (p=0.008), compared with those with non-A blood type. In addition, male patients with an A blood group with a high blood lymphocyte level showeda tendency towards better survival in UICC stage III (p=0.096). Conclusions: ABO blood group status is not associated with the prognosis of patients with NPC. Additionally, blood group A male NPC patients with high VcA-IgA level or high blood lymphocyte counts might be correlated with a favorable prognosis in UICC stage II or III, respectively.     

Association of ABO Blood Group and Risk of Lung Cancer in a Multicenter Study in Turkey

Background: The ABO blood groups and Rh factor may affect the risk of lung cancer. Materials and Methods:We analyzed 2,044 lung cancer patients with serologically confirmed ABO/Rh blood group. A group of 3,022,883healthy blood donors of Turkish Red Crescent was identified as a control group. We compared the distributionsof ABO/Rh blood group between them. Results: The median age was 62 years (range: 17-90). There was a clearmale predominance (84% vs. 16%). Overall distributions of ABO blood groups were significantly differentbetween patients and controls (p=0.01). There were also significant differences between patients and controls withrespect to Rh positive vs. Rh negative (p=0.04) and O vs. non-O (p=0.002). There were no statistically significantdifferences of blood groups with respect to sex, age, or histology. Conclusions: In the study population, ABOblood types were associated with the lung cancer. Having non-O blood type and Rh-negative feature increasedthe risk of lung cancer. However, further prospective studies are necessary to define the mechanisms by whichABO blood type may influence the lung cancer risk.     

Prognostic Impact of ABO Blood Group on Survival in Patients With Malignant Lymphoma

BackgroundThe ABO blood group is reported to be associated with survival for several types of malignancy. We conducted a retrospective study to evaluate the prognostic significance of the ABO blood group in patients with malignant lymphoma.Patients and MethodsA total of 523 patients with malignant lymphoma were included in this study. The primary outcome measured was the association between the ABO blood group and survival.ResultsPatients with blood group B had shorter 5-year overall survival (OS) than patients with non-B blood groups (40.9% vs. 57.3%; P < .01). Among 240 patients with diffuse large B-cell lymphoma (DLBCL), patients with blood group B had shorter 5-year OS in comparison with patients with non-B blood groups (36.3% vs. 56.9%; P < .01). Among male patients with DLBCL, those with blood group B had significantly shorter 5-year OS than those with non-B blood groups (27.5% vs. 55.8%; P = .003). On the other hand, there was no significant difference in the survival between female patients with blood group B and those with non-B blood groups (5-year OS: 49.2% vs. 58.2%; P = .67). A multivariate analysis demonstrated that blood group B (hazard ratio, 1.83; 95% confidence interval, 1.21-2.78; P = .04) was an independent predictor of shorter OS in male patients with DLBCL.ConclusionThe ABO blood group is associated with survival in patients with lymphoma. Interestingly, only male patients with DLBCL with blood group B had significantly shorter OS than those male patients with DLBCL with non-B blood groups.     

肝癌患者同胞罹患原发性肝癌的因素及特征

本文对１５２例具有同胞患肝癌家族史的原发性肝癌先证者进行分析，结果表明：该组人群ＨＢＶ感染率为８１．５８％，感染标记类型有１２种，其中６８％为抗一ＨＢｃ阳性伴ＨＢｓＡｇ和（或）抗－ＨＢｅ阳性；发病高峰年龄为３０～４９岁（占７２％）；兄弟同患肝癌（６７．１１％）显著多于兄妹、姐弟同患，更显著多于姐妹同患（Ｐ＜０．００１），但伴有母患肝癌家族史的患者女性同胞也易患肝癌（Ｐ＜０．０２５）。提示具有同胞患肝癌史、年龄３０～４９岁、尤其是抗－ＨＢｃ阳性伴ＨＢｓＡｇ和（或）抗－ＨＢｅ阳性的男性乙肝患者为肝癌患者一级亲属中原发性肝癌最易感人群，应密切关注，警惕肝癌发生。     

Association between ABO Genotype and Risk of Hepatocellular Carcinoma in Koreans

Background: Associations between ABO blood groups and risk of several malignancies have been reported,although there are limited data regarding hepatocellular carcinoma (HCC). The aim of this study was toinvestigate any possible association between the ABO genotype, especially blood group A, and HCC risk inKoreans. Materials and Methods: We conducted a case-control study of 1,538 patients with newly diagnosedHCC at Chonnam National University Hwasun Hospital and 1,305 randomly selected members of the generalpopulation. The ABO genotype was determined by multicolor real-time polymerase chain reaction (PCR)using displacing probes. Adjusted odds ratios (aORs) and their 95% confidence intervals (CIs) were calculatedusing logistic regression models with adjustment for gender, age, smoking, alcohol drinking, and hepatitis Band C status. Results: The risk of HCC in genotype AA was significantly higher than in OO (aOR=1.773, 95%CI=1.161-2.705). The risk in blood group A was also higher than in blood group O (aOR=1.448, 95% CI=1.0051.897). No significant difference was found for the AA, BO, BB, and AB genotypes, or blood group B and AB.Conclusions: Blood group A and genotype AA showed the highest risks of HCC in a Korean population. Nosignificant difference was found for the AO, BO, BB, and AB genotypes, or blood group B and AB.     

幽门螺杆菌感染、十二指肠溃疡及家族史与胃癌发生的相关性

目的 探讨幽门螺杆菌感染、十二指肠溃疡以及家族史与胃癌发病的相关性.方法 选取256例胃癌患者均为随访时仍存活的新发病例.分析幽门螺旋杆菌感染、十二指肠溃疡及家族史与胃癌发生的相关性.结果 共调查128对.本研究中胃癌家族史即病例组和对照组研究对象的一级亲属(父母、兄弟姐妹、子女)中有胃癌患者.有胃癌家族史的比例为23.39%,显著高于对照组(15.62%)(P=0.045).对变量进行Logistic回归分析,Hp阳性和十二指肠溃疡与胃癌的发生相关(P<0.05).结论 Hp感染及十二指肠溃疡是胃癌危险因素中的显著危险因子.     

恶性肿瘤家族史与乳腺癌患者临床病理特征的关系CSCD

目的探讨恶性肿瘤家族史(MN-FH)与乳腺癌患者临床病理特征之间的关系。方法回顾性分析东南大学附属中大医院2016年1月—2018年12月收治的417例乳腺癌患者的临床病理资料,根据有无MN-FH分成两组。采用χ2检验分析两组患者临床病理特征之间的关系。结果417例乳腺癌患者中,有MN-FH者67例(16.1%)。有MN-FH组的患者有更高比例的脉管癌栓(P=0.046)和淋巴结转移(P=0.023),肿瘤更易表现为ER阴性(P=0.025)、PR阴性(P=0.031)和HER2阳性(P=0.041)。进一步亚组分析发现,有乳腺癌家族史的患者较无MN-FH的患者有更晚的肿瘤分期(P=0.011),肿瘤更易表现为三阴性和HER2扩增型(P=0.010)。其他恶性肿瘤家族史的患者较无MN-FH的患者有更高比例的脉管癌栓(P=0.036)和淋巴结转移(P=0.034)。结论有MN-FH的乳腺癌患者肿瘤恶性程度更高,对于有MN-FH的人群体检非常重要。     

Clinical and Pathological Analyses of Patients with a Family History of Colorectal Cancer

Patients who were registered by the Japanese Society for Cancerof the Colon and Rectum between 1978 and 1983 were examinedclinically and pathologically, in terms of colorectal cancerwith familial accumulation. The incidence of patients with afamily history of colorectal cancer (FH⁺ group)—patientswith adenomatosis coli were excluded—was 6.5% in 15,369colorectal cancer patients. The incidence of patients with afamily history of malignant tumors other than colorectal cancerwas 27.7%. Comparison of the FH⁺ group with the FH^– group(patients without a family history of colorectal cancer) revealedthe incidence of colonic cancer to be significantly higher thanthat of rectal cancer in the FH⁺ group (P<0.01). The patientswith colonic cancer in the FH⁺ group were significantly youngerthan those in the FH^– group (P<0.01), but there wasno age-dependent difference between patients with rectal cancerin the two groups. There was no difference in sex ratio andthere was little difference in the subsite of the primary lesionin the colon between the FH⁺ and FH^– groups. The incidenceof multiple primary colorectal cancer was significantly higherin patients with colonic cancer in the FH⁺ group than in theFH^– group (P<0.01). The incidence of multiple primarycancer in sites other than the colon and rectum was significantlyhigher in the FH⁺ group (P<0.01), but no significant differencewas found in the site of lesions. The prognosis of patientsin the FH⁺ group was significantly better than that of thosein the FH^– group; however, there were no differences inbackground factors such as findings of the primary lesion, statusof metastasis, clinical stage and rate of curative resectionbetween the groups.